Samsung (SSNLF)  is best known for its smartphones, but its five-year-old drug arm Bioepris is close to receiving its third drug approval. 

Bioepis is expected to win final approval for rheumatoid arthritis drug called Imraldi that will be offered at a competitive price to the world's top-selling drug Humira from AbbVie Inc (ABBV) - Get Report , the Wall Street Journal reported. Humira's patent expires in October 2018. 

TheStreet compiled a list detailing what the biggest tech companies, including Apple (AAPL) - Get Report and Alphabet's (GOOGL) - Get Report Google, are doing right now in healthcare. 

Editors' pick: Originally published June 24.

Don't miss these top stories from TheStreet: